LONZA GROUP UNSP.ADR 1/10 (LO3A) - Net Assets
Based on the latest financial reports, LONZA GROUP UNSP.ADR 1/10 (LO3A) has net assets worth €7.97 Billion EUR (≈ $9.31 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€17.91 Billion ≈ $20.94 Billion USD) and total liabilities (€9.94 Billion ≈ $11.62 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore LONZA GROUP UNSP.ADR 1/10 asset portfolio for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €7.97 Billion |
| % of Total Assets | 44.49% |
| Annual Growth Rate | -4.85% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.3 |
LONZA GROUP UNSP.ADR 1/10 - Net Assets Trend (2022–2025)
This chart illustrates how LONZA GROUP UNSP.ADR 1/10's net assets have evolved over time, based on quarterly financial data. Check LO3A goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for LONZA GROUP UNSP.ADR 1/10 (2022–2025)
The table below shows the annual net assets of LONZA GROUP UNSP.ADR 1/10 from 2022 to 2025. For live valuation and market cap data, see LONZA GROUP UNSP.ADR 1/10 stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €9.19 Billion ≈ $10.74 Billion |
-2.14% |
| 2024-12-31 | €9.39 Billion ≈ $10.98 Billion |
-1.30% |
| 2023-12-31 | €9.51 Billion ≈ $11.12 Billion |
-10.81% |
| 2022-12-31 | €10.66 Billion ≈ $12.47 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to LONZA GROUP UNSP.ADR 1/10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 23.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €9.92 Billion | 108.57% |
| Total Equity | €9.13 Billion | 100.00% |
LONZA GROUP UNSP.ADR 1/10 Competitors by Market Cap
The table below lists competitors of LONZA GROUP UNSP.ADR 1/10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Becton Dickinson and Company
NYSE:BDX
|
$41.17 Billion |
|
Thomson Reuters Corp
TO:TRI
|
$41.18 Billion |
|
RECRUIT HLD.UNSP.ADR/02
F:1RHA
|
$41.23 Billion |
|
Toyota Tsusho Corp
NYSE:TYHOY
|
$41.24 Billion |
|
Unimicron Technology Corp
TW:3037
|
$40.92 Billion |
|
KB Financial Group Inc
NYSE:KB
|
$40.86 Billion |
|
MSCI Inc
NYSE:MSCI
|
$40.85 Billion |
|
Franco-Nevada Corporation
TO:FNV
|
$40.83 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LONZA GROUP UNSP.ADR 1/10's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,328,000,000 to 9,134,000,000, a change of -194,000,000 (-2.1%).
- Net loss of 275,000,000 reduced equity.
- Dividend payments of 282,000,000 reduced retained earnings.
- Share repurchases of 518,000,000 reduced equity.
- New share issuances of 11,000,000 increased equity.
- Other factors increased equity by 870,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-275.00 Million | -3.01% |
| Dividends Paid | €282.00 Million | -3.09% |
| Share Repurchases | €518.00 Million | -5.67% |
| Share Issuances | €11.00 Million | +0.12% |
| Other Changes | €870.00 Million | +9.52% |
| Total Change | €- | -2.08% |
Book Value vs Market Value Analysis
This analysis compares LONZA GROUP UNSP.ADR 1/10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.42x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | €142.66 | €54.50 | x |
| 2023-12-31 | €131.07 | €54.50 | x |
| 2024-12-31 | €132.06 | €54.50 | x |
| 2025-12-31 | €130.21 | €54.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LONZA GROUP UNSP.ADR 1/10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.21%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 2.08x
- Recent ROE (-3.01%) is below the historical average (5.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 11.47% | 19.52% | 0.36x | 1.64x | €155.30 Million |
| 2023 | 6.92% | 9.74% | 0.40x | 1.78x | €-291.20 Million |
| 2024 | 6.82% | 11.61% | 0.28x | 2.12x | €-296.80 Million |
| 2025 | -3.01% | -4.21% | 0.34x | 2.08x | €-1.19 Billion |
Industry Comparison
This section compares LONZA GROUP UNSP.ADR 1/10's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,781,338,041
- Average return on equity (ROE) among peers: -5.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LONZA GROUP UNSP.ADR 1/10 (LO3A) | €7.97 Billion | 11.47% | 1.25x | $41.04 Billion |
| IZOTROPIC CORP. (1R3) | $-374.59K | 0.00% | 0.00x | $11.37 Million |
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | $10.41 Million | -90.99% | 0.83x | $1.06 Million |
| HANGZHOU TIGERMED CO. H 1 (5HZ1) | $20.61 Billion | 13.95% | 0.15x | $572.90 Million |
| Check-Cap Ltd (7CC) | $3.44 Million | 120.45% | 1.18x | $6.69 Million |
| INTERGRATED DIA.H DL 025 (8I8) | $2.45 Billion | 22.11% | 1.16x | $275.93 Million |
| GENETIC ANALYSIS NK -60 (8V8) | $44.14 Million | -64.05% | 0.46x | $2.85 Million |
| GENINCODE PLC LS -01 (9PL) | $13.72 Million | -30.19% | 0.11x | $5.93 Million |
| INOVIQ LTD. (EGQ0) | $28.29 Million | -64.31% | 0.09x | $17.45 Million |
| Eurofins Scientific SE (ESF0) | $3.72 Billion | 14.51% | 1.31x | $11.18 Billion |
| ICON Public Limited Company (IJF) | $945.17 Million | 27.74% | 0.93x | $7.52 Billion |
About LONZA GROUP UNSP.ADR 1/10
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract develo… Read more